AZD1613

Phase 1Small molecule

AZD1613 is one of 10 small molecule programs targeting Autosomal Dominant Polycystic Kidney Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autosomal Dominant Polycystic Kidney DiseaseRecruiting

Autosomal Dominant Polycystic Kidney DiseasePhase 1

Recruiting

Competition

Competitive Landscape

13 competitors in Autosomal Dominant Polycystic Kidney Disease

#DrugCompanyPhaseTrials

Samsca

Otsuka

Approved

11 2

Afinitor

Novartis

Approved

1 3

Jardiance

Boehringer Ingelheim

Approved

3 4

Lanreotide Acetate

AAlbireo, an Ipsen Company

Approved

—5

Lesinurad

EEsperion Therapeutics, Inc.

Approved

—6

Versed

CConrado Roberto Hoffmann Filho

Sandostatin

VX-407

Vertex Pharmaceuticals

Phase 2

2 9

Tripterygium Wilfordii

ZZhi-Hong Liu, M.D.

Preclinical

1 10

AZD1613

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Study completion

NCT06995820

Q2 2027

Phase 1Recruiting

Autosomal Dominant Polycystic Kidney Disease

NCT07228364

Clinical

Trials by Indication[1]

Autosomal Dominant Polycystic Kidney Disease1 trial

A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07228364·40 enrolled

Unspecified1 trial

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of AZD1613 Following Single and Multiple Dose Administration in Healthy Participants

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06995820·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD1613. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD1613 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD1613. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD1613

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Autosomal Dominant Polycystic Kidney Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News